Health Now

U.S. panel endorses 3rd vaccine option from Johnson & Johnson

Associated Press
By Associated Press
1 Min Read Feb. 28, 2021 | 5 years Ago
Go Ad-Free today

WASHINGTON — A U.S. advisory panel has endorsed the new one-dose covid-19 vaccine from Johnson & Johnson as a third option to bolster the national effort against the coronavirus pandemic.

Advisers to the Centers for Disease Control and Prevention voted overwhelmingly to recommend the vaccine for adults 18 years old and up. The ruling followed emergency clearance of the vaccine by U.S. regulators a day earlier.

Members of the group emphasized that all three vaccines now available in the U.S. are highly protective against the worst effects of the virus, including hospitalization and death.

J&J plans to ship several million vaccine doses to states in the coming week, delivering a total of 20 million shots by the end of March. Health officials are eager to have an easier-to-use vaccine against covid-19, which has killed more than 511,000 Americans and continues to mutate in troubling ways.

CDC recommendations are not binding on state governments or doctors, but are widely heeded by the medical community. The same CDC panel previously recommended use of the two vaccines from Pfizer and Moderna authorized in December.

Share

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options